ReviewBiomolecules2020
Cannabidiol: A Potential New Alternative for the Treatment of Anxiety, Depression, and Psychotic Disorders.
Review in Biomolecules, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 130 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
130 citing papers in PubMed, 5 syntheses or guidelines pooled it, 293 citations in OpenAlex.
- Effects of cannabidiol on anxiety- and depressive-like behaviors and cognition: a systematic review and meta-analysis of preclinical studies.Molecular psychiatry · 2026Pooled it
- The Effect of Cannabidiol on Performance and Post-Load Recovery among Healthy and Physically Active Individuals: A Systematic Review.Nutrients · 2024Pooled it
- Endocannabinoid levels in female-sexed individuals with diagnosed depression: a systematic review.BMC women's health · 2024Pooled it
- Efficacy of cannabinoids in neurodevelopmental and neuropsychiatric disorders among children and adolescents: a systematic review.European child & adolescent psychiatry · 2024Pooled it
- Systematic review and rationale of using psychedelics in the treatment of cannabis use disorder.Frontiers in psychiatry · 2023Pooled it
- Phase 2, open-label INSPIRE trial to assess the tolerability and effectiveness of transdermal cannabidiol gel in children and adolescents with 22q11.2 deletion syndrome (ZYN2-CL-031).Journal of neurodevelopmental disorders · 2026Trial
- CBD attenuates amygdala response to negative emotional stimuli in individuals with alcohol use disorder - a randomized controlled trial.Psychopharmacology · 2026Trial
- Long-term safety and tolerability of transdermal cannabidiol gel in children and adolescents with Fragile X syndrome (ZYN2-CL-017): an interim analysis of an ongoing open-label extension study.Journal of neurodevelopmental disorders · 2025Trial
- Investigating the Relationship Between Cannabis Expectancies and Anxiety, Depression, and Pain Responses After Acute Flower and Edible Cannabis Use.Cannabis and cannabinoid research · 2025Trial
- The impact of cannabidiol placebo on amygdala-based neural responses to an acute stressor.Journal of psychopharmacology (Oxford, England) · 2024Trial
- Acute and Extended Anxiolytic Effects of Cannabidiol in Cannabis Flower: A Quasi-ExperimentalCannabis and cannabinoid research · 2024Trial
- Does a broad-spectrum cannabidiol supplement improve performance in a 10-min cycle ergometer performance-test?European journal of sport science · 2024Trial
- The impact of cannabidiol placebo on responses to an acute stressor: A replication and proof of concept study.Journal of psychopharmacology (Oxford, England) · 2024Trial
- Eight Weeks of Daily Cannabidiol Supplementation Improves Sleep Quality and Immune Cell Cytotoxicity.Nutrients · 2023Trial
- Cannabidiol for anxiety and depressive symptoms in primary brain tumors: Results from an early-terminated, placebo-controlled, crossover randomized clinical trial.Neuro-oncology practice · 2026Article
- Natural Products as GPCR-Targeting Antidepressant Candidates: Advances and Opportunities.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Cannabidiol extending beyond neuroprotection toward neuronal repair: A potential regenerative modulator.Neural regeneration research · 2026Article
- Might modulation of the endocannabinoid system provide a potential dual therapeutic strategy for osteoporosis and depression?General psychiatry · 2026Article
- Cannabidiol in Dietary Supplements: Characteristics, Routes of Administration, Bioavailability, and Research Challenges.Molecules (Basel, Switzerland) · 2026Review
- A qualitative study on cannabis use for harm reduction and pain among veterans enrolled in an SUD treatment program.Harm reduction journal · 2026Article
70 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The potential therapeutic use of some
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.